Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
PDF Library
RSS Feeds
Free Trial Request
Subscribe
Advertising
PR Newswire
UsernamePublicRestriction
Tags:
Medical Device Regulation Regulation

Epigenomics' Epi proColon Blood Test Finally Makes The Grade With FDA

This article was originally published in The Gray Sheet

  • News

Executive Summary

FDA approved the first blood-based colorectal cancer screening test, developed by Epigenomics, after a challenging regulatory path for the product, including a 2014 not-approvable letter.

Table

View full table

Advertisement

Related Content

Medtech Insight
Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test

Topics

Related Companies

Advertisement
Tags:
Medical Device Regulation Regulation
UsernamePublicRestriction

Register

MT034691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By